In this video, Emilio Portaccio, MD, University of Florence, Florence, Italy, briefly discusses how a better understanding of relapse-associated worsening (RAW) and progression independent from relapse activity (PIRA) will allow for improving outcomes and therapeutic interventions for patients with multiple sclerosis (MS). Dr Portaccio emphasizes the need to widen the definition of disability progression to allow for its accurate assessment in clinical trials and practice. This interview took place at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
VJNeurology